Similar articles for PMID: 31851084

Year	Number of Results
2002	1
2003	1
2007	1
2008	1
2009	2
2011	6
2012	5
2013	6
2014	9
2015	9
2016	13
2017	16
2018	14
2019	19
2020	22
2021	22
2022	17
2023	3
2024	0

1

Add-on sorafenib is beneficial for hepatocellular carcinoma patients with transarterial chemoembolization refractoriness: a real-world experience.

Lin PT, Teng W, Jeng WJ, Hsieh YC, Hung CF, Huang CH, Lui KW, Chen YC, Lin CC, Lin CY, Sheen IS, Lin SM. Lin PT, et al. Eur J Gastroenterol Hepatol. 2020 Sep;32(9):1192-1199. doi: 10.1097/MEG.0000000000001637. Eur J Gastroenterol Hepatol. 2020. PMID: 31851084

2

Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: The phase III STAH trial.

Park JW, Kim YJ, Kim DY, Bae SH, Paik SW, Lee YJ, Kim HY, Lee HC, Han SY, Cheong JY, Kwon OS, Yeon JE, Kim BH, Hwang J. Park JW, et al. J Hepatol. 2019 Apr;70(4):684-691. doi: 10.1016/j.jhep.2018.11.029. Epub 2018 Dec 6. J Hepatol. 2019. PMID: 30529387 Free article. Clinical Trial.

3

Transarterial Infusion of Epirubicin and Cisplatin Combined With Systemic Infusion of 5-Flurouracil Versus Sorafenib for Hepatocellular Carcinoma With Refractoriness of Transarterial Chemoembolization Using Doxorubicin.

Yoo SH, Kwon JH, Nam SW, Lee JY, Kim YW, Shim DJ, Lee SW, Jang JW. Yoo SH, et al. Cancer Control. 2020 Apr-Jun;27(2):1073274820935843. doi: 10.1177/1073274820935843. Cancer Control. 2020. PMID: 32583687 Free PMC article.

4

Radiologic Response Combined with Dermatologic Toxicities is the Most Robust Predictor of Survival Benefits in Patients with Inoperable Hepatocellular Carcinoma After Transarterial Chemoembolization Plus Sorafenib Therapy.

Ye Z, Deng Z, Jiang S, Wang T, Liu L, Jiang K, Zhang Y. Ye Z, et al. Cardiovasc Intervent Radiol. 2021 Sep;44(9):1394-1402. doi: 10.1007/s00270-021-02846-w. Epub 2021 May 4. Cardiovasc Intervent Radiol. 2021. PMID: 33948697 Free PMC article.

5

Prognostic Factors for Survival After Transarterial Chemoembolization Combined with Sorafenib in the Treatment of BCLC Stage B and C Hepatocellular Carcinomas.

Ni JY, Kong J, Sun HL, Chen YT, Luo JH, Wang WD, Chen D, Jiang XY, Xu LF. Ni JY, et al. Acad Radiol. 2018 Apr;25(4):423-429. doi: 10.1016/j.acra.2017.10.018. Epub 2017 Nov 29. Acad Radiol. 2018. PMID: 29198946

6

The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma.

Wu FX, Chen J, Bai T, Zhu SL, Yang TB, Qi LN, Zou L, Li ZH, Ye JZ, Li LQ. Wu FX, et al. BMC Cancer. 2017 Sep 12;17(1):645. doi: 10.1186/s12885-017-3545-5. BMC Cancer. 2017. PMID: 28899349 Free PMC article.

7

Microwave ablation versus sorafenib for intermediate-Stage Hepatocellular carcinoma with transcatheter arterial chemoembolization refractoriness: a propensity score matching analysis.

Chen S, Shi M, Shen L, Qi H, Wan W, Cao F, Xie L, Wu Y, Chen G, Mo J, Zhu G, Ye D, Zhang Y, Feng Z, Xu L, Fan W. Chen S, et al. Int J Hyperthermia. 2020;37(1):384-391. doi: 10.1080/02656736.2020.1752400. Int J Hyperthermia. 2020. PMID: 32323585 Free article.

8

Sorafenib in combination with transarterial chemoembolization improves the survival of patients with unresectable hepatocellular carcinoma: a propensity score matching study.

Bai W, Wang YJ, Zhao Y, Qi XS, Yin ZX, He CY, Li RJ, Wu KC, Xia JL, Fan DM, Han GH. Bai W, et al. J Dig Dis. 2013 Apr;14(4):181-90. doi: 10.1111/1751-2980.12038. J Dig Dis. 2013. PMID: 23324079 Clinical Trial.

9

Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Sorafenib for Hepatocellular Carcinoma Refractory to Transarterial Chemoembolization: Retrospective Subgroup Analysis of 2 Prospective Trials.

Huang Y, Zhang L, He M, Lai Z, Bu X, Wen D, Li Q, Xu L, Wei W, Zhang Y, Zhou Z, Chen M, Guo R, Shi M, Kan A. Huang Y, et al. Technol Cancer Res Treat. 2022 Jan-Dec;21:15330338221117389. doi: 10.1177/15330338221117389. Technol Cancer Res Treat. 2022. PMID: 36529949 Free PMC article.

10

Survival outcomes of hepatic resection compared with transarterial chemoembolization or sorafenib for hepatocellular carcinoma with portal vein tumor thrombosis.

Lee JM, Jang BK, Lee YJ, Choi WY, Choi SM, Chung WJ, Hwang JS, Kang KJ, Kim YH, Chauhan AK, Park SY, Tak WY, Kweon YO, Kim BS, Lee CH. Lee JM, et al. Clin Mol Hepatol. 2016 Mar;22(1):160-7. doi: 10.3350/cmh.2016.22.1.160. Epub 2016 Mar 28. Clin Mol Hepatol. 2016. PMID: 27044767 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

146 results

Results by year